Advertisement

News in Ovarian Cancer From ESMO 2019


This week, we review two studies from a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2019 focusing on the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with newly diagnosed ovarian cancer.




Advertisement
Advertisement

Advertisement




Advertisement